Development of a bispecific antibody–drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors
Abstract Epithelial cell adhesion molecule (EpCAM), a tumor antigen for antibody–drug conjugates (ADCs), is highly expressed in many epithelial cancers. However, the clinical progress of EpCAM ADCs has been challenging, primarily due to their toxicity in normal high-expression tissues such as the ga...
Saved in:
| Main Authors: | Meiying Luo, Xiaohuan Wang, Guoji Yu, Jing Ji, Long Li, Fan Song |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | Experimental Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40164-025-00624-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting CD44 and EpCAM with Antibody Dye Conjugates for the Photoimmunotherapy of Prostate Cancer
by: Isis Wolf, et al.
Published: (2025-01-01) -
Landscape of cancer associated EpCAM mutations: molecular modeling, predictive insights and impact on patient survival
by: Priyanka S. Dhotare, et al.
Published: (2025-07-01) -
Absence of EpCAM in cervical cancer cells is involved in slug induced epithelial-mesenchymal transition
by: Xian Liu, et al.
Published: (2021-03-01) -
Biological roles and clinical applications of EpCAM in HCC
by: Peng Liu, et al.
Published: (2025-03-01) -
A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy
by: Gerhard Frey, et al.
Published: (2024-12-01)